PT - JOURNAL ARTICLE AU - Vukadinovic, Milos AU - Kwan, Alan C. AU - Yuan, Victoria AU - Salerno, Michael AU - Lee, Daniel C. AU - Albert, Christine M. AU - Cheng, Susan AU - Li, Debiao AU - Ouyang, David AU - Clarke, Shoa L. TI - Deep learning enabled analysis of cardiac sphericity AID - 10.1101/2022.07.20.22277861 DP - 2022 Jan 01 TA - medRxiv PG - 2022.07.20.22277861 4099 - http://medrxiv.org/content/early/2022/07/21/2022.07.20.22277861.short 4100 - http://medrxiv.org/content/early/2022/07/21/2022.07.20.22277861.full AB - Quantification of chamber size and systolic function is a fundamental component of cardiac imaging, as these measurements provide a basis for establishing both diagnosis and appropriate treatment for a spectrum of cardiomyopathies. However, the human heart is a complex structure with significant uncharacterized phenotypic variation beyond traditional metrics of size and function. Characterizing variation in cardiac shape and morphology can add to our ability to understand and classify cardiovascular risk and pathophysiology. We describe deep learning enabled measurement of left ventricle (LV) sphericity using cardiac magnetic resonance imaging data from the UK Biobank and show that among adults with normal LV volumes and systolic function, increased sphericity is associated with increased risk for incident atrial fibrillation (HR 1.31 per SD, 95% CI 1.23-1.38), cardiomyopathy (HR 1.62 per SD, 95% CI 1.29-2.02), and heart failure (HR 1.24, 95% CI 1.11-1.39), independent of traditional risk factors including age, sex, hypertension, and body mass index. Using genome-wide association studies, we identify four loci associated with sphericity at genome-wide significance. These loci harbor known and suspected cardiomyopathy genes. Through genetic correlation and Mendelian randomization, we provide evidence that sphericity may represent a subclinical manifestation of non-ischemic cardiomyopathy.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The source data were publicly available prior to the initiation of this study. UK Biobank data is available with an approved study protocol (https://www.ukbiobank.ac.uk/).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesUK Biobank data is available with an approved study protocol. https://www.ukbiobank.ac.uk/